SNY's Tzield gets FDA nod for kids, Sarclisa SC BLA faces delay
- Posted on April 23, 2026
- By Bing News
- 0 Views
- 1 min read
SNY's Tzield gets FDA nod for kids, Sarclisa SC BLA faces delay
Sanofi SNY announced that the FDA has approved the supplemental biologic license application (sBLA) seeking to expand the use of Tzield (teplizumab) to delay the onset of stage 3 T1D in individuals aged one year and older with stage 2 disease. Separately, the FDA has extended the review timeline for the BLA seeking approval for a subcutaneous (SC) formulation of its cancer drug, Sarclisa, for treating multiple myeloma (MM) by up to three months....
